Connect with:
Friday / November 8. 2024

logo
mobile-logo
HomePosts Tagged "Novozymes"
Company News, World

The announcement of the name marks an important milestone towards uniting the two companies

Novozymes and Chr. Hansen has announced that the name of the future combined company will be ‘Novonesis’. Novonesis means ‘A new beginning’ and derives from the Greek word ‘genesis’. According to the companies, the name reflects a new era of biosolutions where innovation in biological sciences and technology will offer solutions to solve some of the biggest challenges facing humanity.
Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. The announcement of the name marks an important milestone towards uniting the two companies.

“Novonesis reflects where we came from, what we can achieve, and what we will become together. We are dedicated to harness the transformative potential of biology. Building on our legacy of developing innovative biosolutions, we stand ready to unlock unprecedented opportunities,” said Ester Baiget, President and CEO of Novozymes. “In Novonesis, we will unite the brightest minds and the best science and technology in the field to help customers and businesses prosper while enabling to solve some of the greatest challenges we all face. We are here to start an era of biosolutions. That is why we have chosen to call our new company Novonesis which means ‘A new beginning’.”

The announcement of the name marks an

Animal Health, Company News, Live Stock, World

The two companies have signed a joint development and commercialisation agreement to launch the feed additive Ablacto

Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialisation agreement to finish development and launch the biosolution Ablacto+. The promising product can potentially stabilize the gut of piglets and reduce the severity of post-weaning diarrhoea (PWD).

PWD is a major, global swine health challenge caused by E. coli infections in newly weaned pigs. Globally, PWD is estimated to lead to a loss of production of EUR 1-2 billion per year. Additionally, PWD is considered the main driver for antibiotic use in weaner pigs. In Denmark alone, antibiotic consumption among weaners constitutes 49 per cent of the total use of antibiotics in pigs (DANMAP 2021)1.

“Post-weaning diarrhoea is one of the biggest challenges in the global swine industry. We are very excited to join this partnership with Bactolife. Together, we will be able to develop innovative solutions that can stabilise the gut of piglets, increase productivity, and significantly reduce the use of antibiotic use among pigs,” says Sofie Louise Trads, Director, of Animal Health at Novozymes.

“We are extremely happy to partner with Novozymes on this promising product. This is a major validation of Bactolife’s technology platform, and with a strong commercial partnership in the Animal Health space like Novozymes, we believe there is significant business potential for both parties,” says Sebastian Søderberg, CEO at Bactolife.

”Since we started Bactolife, Ablacto+ has been leading the way for our technology platform, validating the impact that highly specific binding proteins can have on complex problems, such as PWD. Ablacto+ will support animal welfare and global health as antibiotics use is reduced and animals remain healthy,” says Sandra Wingaard Thrane, CSO at Bactolife.


The product candidate, Ablacto+, is a functional feed additive that consists of binding proteins with a specific mode of action. Binding proteins are science-backed, versatile ingredients that significantly reduce the risk of gastrointestinal infections including PWD.

Novozymes and Bactolife believe that their new biosolution with its novel mode of action can be a game changer in reducing antibiotic consumption in pigs and thereby reducing the risk of antibiotic resistance development in both pigs and humans.

ABLACTO+ has already shown promising results in large-scale swine trials, and Novozymes and Bactolife will now collaborate to finalise the product development and subsequently commercialise the Ablacto+ product. Novozymes will develop and produce the final product and has the global exclusive marketing and sales responsibility.

The two companies have signed a joint

Biostimulants, Company News, Malaysia

By collaborating with Novozymes, Azelis will be able to tap into its knowledge and solutions for the benefit of company’s long-term A&ES strategy in Asia Pacific.

Azelis, a leading innovation service provider in the specialty chemicals and food ingredients industry, is pleased to announce the expansion of its distribution partnership with Novozymes, a leader in biological solutions. Effective immediately, Azelis will distribute Novozymes’ best-in-class bio-based agriculture (“BioAg”) solutions, including its portfolio of microbial inoculant, biostimulant and biocontrol solutions, in Malaysia. This mandate builds on Azelis’ successful partnership with Novozymes across Asia Pacific in other markets, from Home Care & Industrial Cleaning in the Philippines to Food & Nutrition in New Zealand.

Novozymes’ dynamic biological solutions are derived from naturally occurring microbes and biomolecules. Their portfolio of solutions drives crop performance, improves nutrient use efficiency, and helps crops manage abiotic stresses through natural processes. The addition of Novozymes’ innovative products strengthens Azelis’ lateral value chain in the Agricultural & Environmental Solutions (“A&ES”) industry, allowing the group to offer technical solutions that include the latest BioAg technology and solutions.

Muhammad Iqbal, Commercial Head Agriculture SEA, Novozymes, said, “Through this partnership, customers will have access to solutions that leverage our combined expertise – Novozymes’ BioAg knowledge and Azelis’ in-depth crop nutrition expertise, leading to new opportunities for growth. Additionally, Azelis’ experienced teams of sales and technical experts, along with their established agrochemical presence across Southeast Asia, will ensure Novozymes’ innovative portfolio of bio solutions reach a wider range of customers in the region.”

Antonius Prihantono, Azelis Asia Pacific Market Segment Director Agrochemicals, commented, “We are pleased to be able to include Novozymes’ biological solutions in our portfolio, as BioAg products are the future of the Agricultural industry. By collaborating with Novozymes, we will be able to tap into their knowledge and solutions for the benefit of our long-term A&ES strategy in Asia Pacific. Together we plan to develop field trial protocols, evaluate trial results, and share best practices to ensure our common goal of bringing first-class BioAg solutions to the market.”

By collaborating with Novozymes, Azelis will be

Agro chems – Fertilizers, Agrotech, Biostimulants, Company News, North America

First commercial sales are expected to commence in the second half of 2023, after receipt of the required regulatory approvals.

Plant Health Care plc and Novozymes South Asia Pvt. Ltd. have signed an agreement for the exclusive distribution of Harpinab for use in sugar cane production in India. First commercial sales are expected to commence in the second half of 2023, after receipt of the required regulatory approvals.

This is the first product introduced into India by PHC. India is the world’s second largest producer of sugar cane with about five million hectares under cultivation. Harpinab has been used on more than 180,000 hectares of sugar cane in Brazil since the launch in 2018.

Evaluated by Novozymes in prior growing seasons in India, the application of Harpinab to sugar cane bolstered crop yield by more than 10 per cent on average. Harpinab works by triggering the plant’s own self defence systems, in a manner similar to vaccinations in humans, with crops responding with improved quality, nutrient use efficiency, tolerance to abiotic stress and ultimately, increased yield. Being a biological product, Harpinab has a very favourable human and environmental safety profile.

First commercial sales are expected to commence

Agrotech, Company News

Evoca helps sustainably control economically important fungal diseases such as Botrytis and powdery mildew in fruits and vegetables.

Novozymes and Biotalys, an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions have announced the successful outcome of the feasibility study for Evoca™*, Biotalys’ first proprietary biocontrol product candidate. 

Novozymes obtained proof of concept for a new manufacturing process that offers potential significant cost of goods and scaling advantages, thereby broadening the commercial potential of Evoca as a novel biofungicide.

Evoca is Biotalys’ first innovative protein-based biofungicide developed on the company’s AGROBODY Foundry™ platform which platform allows Biotalys to discover and develop novel biological food protection solutions that combine high efficacy, consistency and safety, with new modes of action to fight resistance. 

Evoca helps sustainably control economically important fungal diseases such as Botrytis and powdery mildew in fruits and vegetables.

“Thanks to its leading protein fermentation expertise, Novozymes has been able to further increase the efficiency of production for Evoca,” said Patrice Sellès, the CEO of Biotalys. “We will now work on a deeper partnership with Novozymes and explore strategic supply and commercialization agreements for the future generation of Evoca while continuing our ongoing internal development activities.”
“Now one step closer to large-scale production, Biotalys and Novozymes have successfully collaborated to provide the industry and growers new ways to safely control damaging pests and diseases and deliver our shared goal of providing highly effective solutions so growers can sustainably feed the world.” Noted Thomas Batchelor, Vice President, Agriculture Marketing and Strategy of Novozymes. 

Evoca helps sustainably control economically important fungal

Agrotech, Company News, North America, R&D

Both companies expect that trials, which are taking place in the Midwestern US, will begin to yield data in November 2022, ahead of the 2023 growing season.

 In a move designed to provide additional, efficacious solutions for growers of traditional row crops, leading ag bio companies Certis Biologicals and Novozymes are jointly developing their technologies as solutions for highly effective control of fungal disease. Field trials are currently underway that will test combinations of Certis Biologicals’ innovative biofungicide active ingredient with new Novozymes actives recently registered for use in the marketplace.

“The biopesticide expertise and leadership of Certis, together with the innovation of Novozymes, is a powerful partnership that will bring new solutions to row crop growers at a time when effective crop protection is more crucial than ever,” said Amy O’Shea, Certis Biologicals President & CEO. “Growers need innovative solutions, and we are proud to be part of bringing those solutions to the marketplace with Novozymes.”

“The recent US EPA registration of Novozymes LCO Promoter technologies opens a gateway for new collaborations with innovative, first mover partners like Certis Biologicals,” said Jason Ward, Head of North America, BioAg Commercial Operations at Novozymes.

Both companies expect that trials, which are taking place in the Midwestern US, will begin to yield data in November 2022, ahead of the 2023 growing season.

“We believe that the power of our innovative biofungicide technology combined with Novozymes innovations will bring a level of biological efficacy to row crops that is unseen in the market today,” said Rob Gibson, Certis Biologicals Global Portfolio Manager. “Our technical experts anticipate significant protection against spot, rust and blight when foliar applied. Through soil application, we have witnessed control against Rhizoctonia, Fusarium and Pythium. This level of protection in a single solution will consistently deliver value back to the grower.”

“Novozymes BioAg has hundreds of trial results across many years and crops documenting LCO Promoter yield increase. LCO is an ideal premix solution delivering consistent yield increases across a wide range of labeled crops, for instance, 4 to 6 bushels in corn. LCO is highly compatible with most crop protection formulations and is effective at low dosages resulting in unchanged use rate for the existing crop protection product,” said Adam Kayser, BioAg Technical Agronomist at Novozymes.

Both companies expect that trials, which are